Status:
COMPLETED
Compare the Effect of INS Alone and Added LTRA in Treatment of SAR
Lead Sponsor:
Beijing Tongren Hospital
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
18-47 years
Phase:
EARLY_PHASE1
Brief Summary
It is not proven unequivocally whether a combination of an intranasal corticosteroids (INS) and a cysteinyl leukotriene receptor antagonist has greater efficacy than INS in the treatment of severe all...
Eligibility Criteria
Inclusion
- moderate to severe seasonal allergic rhinitis
- confirmed to had a diagnosis of SAR and also shown to be sensitized to mugwort allergen
- had not received any therapies for AR or antibiotics for at least 7 days before their outpatient clinic visit prior to the study
Exclusion
- smokers
- asthma (based on patient's history and pulmonary function tests)
- had any other chronic disease
- pregnant women
Key Trial Info
Start Date :
June 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2016
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04077892
Start Date
June 1 2016
End Date
September 30 2016
Last Update
September 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tongren Hospital
Beijing, Beijing Municipality, China, 100730